”Wednesday’s deal gives Day One its fourth cancer programme. The FDA in April approved Day One’s pan-RAF kinase inhibitor Ojemda (tovorafenib) to treat relapsed or refractory low-grade glioma with an activating BRAF alteration. The company’s pipeline also includes MEK 1/2 inhibitor pima...